Page 26 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dupont Capital Management Corp lowered its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) by 56.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,727 shares of the company’s stock after selling 29,675 shares during the period. Dupont Capital Management Corp’s holdings […]

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced new...

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Item 1.02 Termination of a Material Definitive Agreement. On June 7, 2022, Karyopharm Therapeutics Inc. received written notice from Biogen MA Inc. that Biogen has elected to terminate the Asset... | June 15, 2022

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) Director Deepika Pakianathan sold 325,977 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $6.50, for a total transaction of $2,118,850.50. Following the transaction, the director now owns 18,731 shares of the company’s stock, […]